3 results on '"Alrohimi, A."'
Search Results
2. Risk of hemorrhagic transformation with early use of direct oral anticoagulants after acute ischemic stroke: A pooled analysis of prospective studies and randomized trials
- Author
-
Anas Alrohimi, David Z Rose, W Scott Burgin, Swetha Renati, Nicholas Corbin Hilker, Wei Deng, Guilherme H Oliveira, Theresa M Beckie, Arthur J Labovitz, Michael G Fradley, Nhi Tran, Laura C Gioia, Mahesh Kate, Kelvin Ng, Dar Dowlatshahi, Thalia S Field, Shelagh B Coutts, Muzzafar Siddiqui, Michael D Hill, Jodi Miller, Glen Jickling, Ashfaq Shuaib, Brian Buck, Mike Sharma, and Ken S Butcher
- Subjects
Neurology - Abstract
Introduction: Precise risk of hemorrhagic transformation (HT) in acute ischemic stroke (AIS) remains unknown, leading to delays in anticoagulation initiation for secondary stroke prevention. We sought to assess the rate of HT associated with direct oral anticoagulant (DOAC) initiation within and beyond 48 h post-AIS. Methods: A pooled analysis of DOAC initiation within 14 days of AIS or transient ischemic attack (TIA) was conducted with six studies (four prospective open label treatment, blinded outcome studies and two randomized trials; NCT02295826 and NCT02283294). The primary endpoint was incident radiographic HT on follow-up imaging (days 7–30). Secondary endpoints included symptomatic HT, new parenchymal hemorrhage, recurrent ischemic events, extracranial hemorrhage, study period mortality, and follow-up modified Rankin Scale score. The results were reported as odds ratio (OR) or hazard ratio (HR) with 95% confidence interval (CI). Results: We evaluated 509 patients; median infarct volume was 1.5 (0.1–7.8) ml, and median National Institutes of Health Stroke Scale was 2 (0–3). Incident radiographic HT was seen on follow-up scan in 34 (6.8%) patients. DOAC initiation within 48 h from index event was not associated with incident HT (adjusted OR 0.67, [0.30–1.50] P = 0.32). No patients developed symptomatic HT. Conversely, 31 (6.1%) patients developed recurrent ischemic events, 64% of which occurred within 14 days. Initiating a DOAC within 48 h of onset was associated with similar recurrent ischemic event rates compared with those in which treatment was delayed (HR: 0.42, [0.17–1.008] P = 0.052). In contrast to HT, recurrent ischemic events were associated with poor functional outcomes (OR = 6.8, [2.84–16.24], p Conclusions: In this pooled analysis, initiation of DOAC within 48 h post-stroke was not associated with increased incident risk of HT, and none developed symptomatic HT. The analysis was underpowered to determine the effect of early DOAC use upon recurrent ischemic events.
- Published
- 2023
- Full Text
- View/download PDF
3. Control-matched octo/nonagenarian outcomes in acute basilar artery occlusions treated with mechanical thrombectomy-analysis of the PC-SEARCH thrombectomy registry.
- Author
-
Mierzwa AT, Prologo-Richardson P, Kasab SA, Nelson A, Gutierrez SO, Vivanco-Suarez J, Farooqui M, Jadhav AP, Desai S, Toth G, Alrohimi A, Nguyen TN, Klein P, Abdalkader M, Salahuddin H, Wilseck Z, Pandey A, Koduri S, Vora N, Aladamat N, Gharaibeh K, Afreen E, Zaidi S, and Jumaa M
- Abstract
Introduction: Age is often used as a predictor in determining outcomes in large vessel occlusions treated with mechanical thrombectomy. However, limited data exist for octo/nonagenarian outcomes compared to younger individuals in acute basilar artery occlusions treated with thrombectomy., Methods: Patient data were obtained from the PC-SEARCH Thrombectomy Registry which consists of 444 acute basilar artery occlusions treated with mechanical thrombectomy. Individuals were dichotomized based on age (>80 and ≤80 years old). Primary outcome was defined as modified Rankin Scale of 0-3 at 90 days. Logistic and multivariate regression, as well as control-matched analysis, were performed., Results: There were 373 and 71 patients in the younger and older cohorts, respectively. Gender, ethnicity, smoking status, atrial fibrillation, and coronary artery disease were noted to be significantly different between cohorts. At 90 days, 178 (47.7%) and 23 (32.4%) patients achieved primary outcome at 90 days (p = 0.02), however, after controlling for potentially confounding factors this association lost significance (OR 0.50 95% CI 0.24-1.05; p = 0.07). There were 84 patients included in the control matched analysis and demonstrated no significant differences on multivariate analysis between cohorts (OR 0.68 95% CI 0.25-1.84; p = 0.45)., Interpretation: Octa/nonagenarians presenting with an acute basilar artery occlusion treated with mechanical thrombectomy can achieve acceptable rates of favorable functional outcomes compared to younger individuals with similar baseline demographic and stroke characteristics., Competing Interests: Authors’ contributionThe authors who have contributed to at least one of the key contributions that justify authorship, including (1) conception and design of the study (ATM, PPR, MJ), (2) acquisition and analysis of data (ATM, PPR, MJ) or (3) drafting a significant portion of the manuscript or figures (i.e., a substantial contribution beyond copy editing and approval of the final draft, which is expected of all authors) (ATM, PPR, MJ). Individuals who contributed data acquisition (including phenotyping and gathering information on patients) but not to the final analysis that is unique to this manuscript (e.g., site investigators in a large clinical trial or contributors to a large patient database) (PC-SEARCH Thrombectomy REGISTRY Group includes: NA, KG, EA, SZ, AN, SAK, SOG, JVS, MF, APJ, SD, GT, AA, TNN, PK, MA, ZW, SV, and NV). Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Mouhammad Jumaa has received general payments (<$1000) and academic funding from Chiesi USA, Genentech, Medtronic, and Stryker. Dr Sami Al Kasab has received general payments (<$1000) from AstraZeneca Pharmaceuticals, MicroVention, and Stryker. Dr Santiago Ortega Gutierrez has received general payments and academic funding from Medtronic, and Siemens Medical Solutions USA, Stryker. Dr Ashutosh P Jadhav has received general payments (<$1000) and academic funding from Medtronic, Viz AI, and Medical Device Business Services, Inc. Dr Toth Gabor has received general payments (<$1000) and academic funding from BioSense Webster, Medtronic, and Stryker. Dr Thanh Nguyen has received academic funding from AtriCure.
- Published
- 2024
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.